-
Posted by
Two Blokes Jul 14 -
Filed in
Stock
-
1 view
The global wet age-related macular degeneration (AMD) market is expanding rapidly due to factors like an aging population, advancements in treatment options, and increased awareness. A leading cause of vision loss in people over 50, wet AMD is primarily treated with anti-VEGF therapies, which dominate the market. Innovations like cell and gene therapy, early detection technologies like OCT, and personalized medicine are shaping the market's future. However, challenges such as high treatment costs and limited access to care persist. Key players like Regeneron and Adverum Biotechnologies are active in R&D, striving to deliver improved, sustainable solutions. The global wet age-related macular degeneration (AMD) market is expanding rapidly due to factors like an aging population, advancements in treatment options, and increased awareness. A leading cause of vision loss in people over 50, wet AMD is primarily treated with anti-VEGF therapies, which dominate the market. Innovations like cell and gene therapy, early detection technologies like OCT, and personalized medicine are shaping the market's future. However, challenges such as high treatment costs and limited access to care persist. Key players like Regeneron and Adverum Biotechnologies are active in R&D, striving to deliver improved, sustainable solutions.
